Edition:
United Kingdom

Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

46.26CHF
10 Dec 2018
Change (% chg)

CHF0.32 (+0.70%)
Prev Close
CHF45.94
Open
CHF45.60
Day's High
CHF47.56
Day's Low
CHF45.60
Volume
63,053
Avg. Vol
73,530
52-wk High
CHF81.45
52-wk Low
CHF44.02

Chart for

About

Basilea Pharmaceutica AG is a Switzerland-based company engaged in the research, development and commercialization of pharmaceutical products. The Company focuses on pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology. The Company has a range of drugs to treat drug-resistant... (more)

Overall

Beta: 1.31
Market Cap(Mil.): CHF947.87
Shares Outstanding(Mil.): 11.86
Dividend: --
Yield (%): --

Financials

  BSLN.S Industry Sector
P/E (TTM): -- 92.25 33.63
EPS (TTM): -4.21 -- --
ROI: -17.70 0.28 15.02
ROE: -- 0.94 16.60

BRIEF-Basilea Pharmaceutica: CHF 10 Million Milestone Payment For Cresemba Sales

* CONTINUED STRONG CRESEMBA® (ISAVUCONAZOLE) U.S. SALES PERFORMANCE BY ASTELLAS PHARMA INC. TRIGGERS CHF 10 MILLION MILESTONE PAYMENT TO BASILEA

10 Dec 2018

BRIEF-Basilea Presents Preclinical Data On Anticancer Drug Candidate Bal101553 At Eortc-Nci-Aacr Symposium

* BASILEA PRESENTS PRECLINICAL DATA ON ITS ANTICANCER DRUG CANDIDATE BAL101553 AT EORTC-NCI-AACR SYMPOSIUM Source text for Eikon: Further company coverage: (Gdynia Newsroom)

14 Nov 2018

BRIEF-Basilea Pharmaceutica Sees 2018 Oper Loss At CHF 25-35 Mln

* H1 OPERATING LOSS OF CHF 20.4 MILLION COMPARED TO CHF 19.1 MILLION IN H1 2017

14 Aug 2018

BRIEF-Basilea Pharmaceutica: Approval For Antifungal Cresemba (Isavuconazole) In Jordan

* HIKMA PHARMACEUTICALS LLC, GAINED REGULATORY APPROVAL FOR ANTIFUNGAL CRESEMBA (ISAVUCONAZOLE) IN JORDAN Source text for Eikon: Further company coverage: (Gdynia Newsroom)

13 Aug 2018

BRIEF-Basilea Starts Clinical Phase 3 Study With Antibiotic Ceftobiprole In Staphylococcus Aureus Bacteremia

* BASILEA STARTS CLINICAL PHASE 3 STUDY WITH ANTIBIOTIC CEFTOBIPROLE IN STAPHYLOCOCCUS AUREUS BACTEREMIA (SAB) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

09 Aug 2018

BRIEF-Basilea Pharmaceutica Reports Receipt Of Payment Based On First Cresemba Approval In Latin America

* REPORTS RECEIPT OF MILESTONE PAYMENT BASED ON FIRST CRESEMBA® APPROVAL IN LATIN AMERICA

19 Jul 2018

BRIEF-Basilea Pharmaceutica Starts Clinical Phase 2A Expansion With Bal101553 In Ovarian Cancer And Glioblastoma

* STARTS CLINICAL PHASE 2A EXPANSION WITH BAL101553 IN OVARIAN CANCER AND GLIOBLASTOMA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

26 Jun 2018

Earnings vs. Estimates